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a
Mutated ras genes (Ha-, Ki- and N-ras) have been found in a
variety of human tumours (Barbacid, 1987). Although in
some tumour types the incidence of mutations is relatively
high (Bos, 1989), the practical value of these findings in
cancer diagnosis and/or prognosis has not been established.
Here we report the detection of a mutation of Ha-ras gene
codon 12 in human urinary bladder carcinomas by using the
polymerase chain reaction (PCR) and relate these findings to
tumour DNA ploidy, a parameter that correlates with clinical
behaviour of urothelial tumours (Koss et al., 1989).
DNA was extracted by standard procedures from 33 fresh
tumour samples and amplified by PCR. Primers designed to
flank a 63 bp fragment containing codon 12 of the Ha-ras
gene (Verlaan-de Vries et al., 1986) were used. DNA of
human placenta and of T24, a bladder tumour cell line that
has GTC (valine) instead of GGC (glycine) at codon 12 of
Ha-ras (Taparowsky et al., 1982) were used as controls.
Briefly, 1 tLg of DNA was added to reaction mixture com-
posed of 10 jsl of 10 x PCR buffer (0.5 M NaCl; 0.1 M Tris,
pH 8.0; 15 mM MgCl2; 0.1% gelatin), 16jtl dNTP (25 mM of
dATP, dCTP, dGTP and dTTP), 8 ftl containing 0.4fig of
each priming oligomer, 5 tlI of 1 x PCR buffer containing 5
units of Taq polymerase and 60 tL of H20. Mineral oil (50 1tl)
was layered over the aqueous phase. To rule out extraneous
contamination of the reaction mixture, control tubes contain-
ing all ingredients, except genomic DNA, were included in all
runs. Forty amplification cycles were carried out with an
automated thermal cycler (Perkin Elmer) using this thermal
profile: 1 min at 94°C, 1 min at 55°C and 3 min at 72°C.
Amplification was evaluated by electrophoresis on 3% wide-
range agarose (Sigma) gels (Figure la). The amplified DNA
was screened on nitrocellulose filters for codon 12 substitu-
tions with 32P-labelled oligonucleotides (DuPont) specific for:
GLY, SER, CYS, ARG, VAL and ALS (Verlaan-de Vries et
al., 1986). Computer-assisted image analysis of Feulgen-
stained touchsmears (Czerniak et al., 1987) was used to
determine the DNA distribution patterns of the tumours.
A normal (glycine) codon 12 of Ha-ras gene (Barbacid,
1987) was found in all 33 tumour samples examined. The
substitution of valine for glycine (G-*T mutation) at codon
12 was clearly evident in 12 tumours, although the signal
varied in intensity (Figure lb). The observed mutation fre-
quency was greater than that reported by using transfection
assays and restriction endonuclease analysis of urothelial
tumours (e.g. Fujita et al., 1984, 1985). No other codon 12
substitution was seen. The synchronous presence of non-
mutated codon 12 in the 12 tumour samples could be due to
normal host cells, tumour cells without the mutation or
tumours cells in which the mutation was confined to only one
allele. The latter two options would reflect the heterogeneity
of tumour cells with respect to Ha-ras gene mutations
(Mulder et al., 1989).
Based on DNA distribution patterns (Figure lc) the
tumours were classified as either diploid or aneuploid (Koss
et al., 1989). Of the 13 diploid tumours, two had the mutated
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Figure 1 Ha-ras gene codon 12 mutation and DNA ploidy in
urinary bladder carcinomas. a, Evaluation of DNA amplification
by agarose gel electrophoresis. Lanes I = size marker; 2 = re-
action mixture without genomic DNA; 3 = human placenta;
4 = T24; 5 = diploid, and 6 = aneuploid bladder tumours. b, Dot-
blot hydridisation with oligonucleotide probe specific for valine at
codon 12. 1A = human placenta; 2A = T24. The remaining dots
represent 33 bladder tumours. Codon 12 mutation is evident in
12 cases. c, DNA distribution patterns of a diploid (top) and an
aneuploid (bottom) bladder tumour.
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gene. By contrast, 10 of the 20 aneuploid tumours had valine
at codon 12 of Ha-ras gene. As shown in Table I the codon
12 substitution correlated better with DNA ploidy than with
histological grading.
The conventional histological classification of bladder car-
cinomas is useful for predicting the clinical behaviour of
grade I and grade III tumours (Koss, 1975). Whereas the
former can recur and are typically non-invasive, the latter
have a strong propensity to invade and metastasise. The
individual behaviour of grade II tumours is not predictable
as some of them remain superficial and others may become
invasive (Koss, 1975). From DNA ploidy measurements it
has been established that the overwhelming majority of grade
I tumours is diploid, that grade III tumours are mostly
aneuploid and that grade II tumours can be either diploid or
aneuploid (Tribukait et al., 1982). Moreover, it has also
Table I Histological grade and DNA ploidy of bladder carcinomas
with mutated codon 12 of Ha-ras gene
Histological grade
n II III
Diploid, mutated (VAL) 2 2 (O) -
Diploid, non-mutated (GLY) 11 11 (0)
Aneuploid, mutated (VAL) 10 3 (0) 7 (5)
Aneuploid, non-mutated (GLY) 10 3 (0) 7 (6)
aNumber of invasive tumours in parentheses.
been determined that with few exceptions diploid tumours
are unlikely to become invasive and that a large proportion
of aneuploid tumours progress to invasive and metastatic
carcinomas (Tribukait et al., 1982).
Our results demonstrate that urothelial tumours with aneu-
ploid DNA distribution patterns, hence aggressive clinical
potential, frequently have a mutation at codon 12 of Ha-ras
gene. Therefore, the detection of a mutated ras gene in
bladder tumours may be of value for identifying aggressive
variants of urothelial carcinomas. Because of the capability
of the PCR to amplify specific DNA sequences from small
numbers of cells (Kumar & Barbacid, 1988; Yang et al.,
1989), one can envision that the test could be performed on
sediments of voided urines. Similarly, retrospective investiga-
tions can be carried out on paraffin-embedded tissues of
patients with known clinical outcome. Moreover, further
studies of mutations at other codons of Ha-, Ki- and N-ras
genes and further clinical follow-up may provide additional
information on the relationship of such alterations and the
clinical behaviour of bladder tumours.
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